| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | SIVEC BIOTECHNOLOGIES, INC. | 1505 W MULBERRY ST | FORT COLLINS | CO | 80521-3355 | LARIMER | USA | R44AI140243 | Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | 000 | 4 | NIH | 10/29/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2021 | SIVEC BIOTECHNOLOGIES, INC. | 1505 W MULBERRY ST | FORT COLLINS | CO | 80521-3355 | LARIMER | USA | R43TR003962 | A large-capacity bacterial platform for the production and targeted delivery of gene editing systems | 000 | 1 | NIH | 4/3/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | SIVEC BIOTECHNOLOGIES LLC | 1505 W MULBERRY ST | FORT COLLINS | CO | 80521-3355 | LARIMER | USA | R43TR003962 | A large-capacity bacterial platform for the production and targeted delivery of gene editing systems | 000 | 1 | NIH | 10/24/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,000,088 ) |
| | 2022 | 2022 | SIVEC BIOTECHNOLOGIES LLC | 1505 W MULBERRY ST | FORT COLLINS | CO | 80521-3355 | LARIMER | USA | R44AI140243 | Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | 000 | 4 | NIH | 5/12/2022 | $1,000,088 |
|
| Issue Date FY: 2021 ( Subtotal = $1,305,803 ) |
| | 2021 | 2021 | SIVEC BIOTECHNOLOGIES LLC | 1505 W MULBERRY ST | FORT COLLINS | CO | 80521-3355 | LARIMER | USA | R43TR003962 | A large-capacity bacterial platform for the production and targeted delivery of gene editing systems | 000 | 1 | NIH | 9/17/2021 | $286,081 |
| | 2021 | 2021 | SIVEC BIOTECHNOLOGIES LLC | 1505 W MULBERRY ST | FORT COLLINS | CO | 80521-3355 | LARIMER | USA | R43TR003962 | A large-capacity bacterial platform for the production and targeted delivery of gene editing systems | 001 | 1 | NIH | 9/21/2021 | $0 |
| | 2021 | 2021 | SIVEC BIOTECHNOLOGIES LLC | 1505 W MULBERRY ST | FORT COLLINS | CO | 80521-3355 | LARIMER | USA | R44AI140243 | Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | 001 | 3 | NIH | 7/23/2021 | $1,019,722 |
| | 2021 | 2020 | SIVEC BIOTECHNOLOGIES LLC | 1505 W MULBERRY ST | FORT COLLINS | CO | 80521-3355 | LARIMER | USA | R44AI140243 | Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | 000 | 2 | NIH | 5/18/2021 | $0 |
| | 2021 | 2018 | SIVEC BIOTECHNOLOGIES LLC | 1505 W MULBERRY ST | FORT COLLINS | CO | 80521-3355 | LARIMER | USA | R43AI140243 | A versatile transkingdom platform for therapeutic nucleic acid delivery to mucosal epithelial tissues | 000 | 1 | NIH | 7/14/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,028,842 ) |
| | 2020 | 2020 | SIVEC BIOTECHNOLOGIES LLC | 1900 E SEADRIFT DR UNIT A | WINDSOR | CO | 80550-3572 | WELD | USA | R44AI140243 | Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | 000 | 2 | NIH | 5/11/2020 | $1,000,000 |
| | 2020 | 2020 | SIVEC BIOTECHNOLOGIES LLC | 1900 E SEADRIFT DR UNIT A | WINDSOR | CO | 80550-3572 | WELD | USA | R44AI140243 | Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | 001 | 2 | NIH | 7/13/2020 | $28,842 |
| | 2020 | 2018 | SIVEC BIOTECHNOLOGIES LLC | 1900 E SEADRIFT DR UNIT A | WINDSOR | CO | 80550-3572 | WELD | USA | R43AI140243 | A versatile transkingdom platform for therapeutic nucleic acid delivery to mucosal epithelial tissues | 000 | 1 | NIH | 5/4/2020 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $293,142 ) |
| | 2018 | 2018 | SIVEC BIOTECHNOLOGIES LLC | 1900 E SEADRIFT DR UNIT A | WINDSOR | CO | 80550-3572 | WELD | USA | R43AI140243 | A versatile transkingdom platform for therapeutic nucleic acid delivery to mucosal epithelial tissues | 001 | 1 | NIH | 8/29/2018 | $293,142 |
| | 2018 | 2018 | SIVEC BIOTECHNOLOGIES LLC | 1900 E SEADRIFT DR UNIT A | WINDSOR | CO | 80550-3572 | WELD | USA | R43AI140243 | A versatile transkingdom platform for therapeutic nucleic acid delivery to mucosal epithelial tissues | 000 | 1 | NIH | 8/20/2018 | $293,142 |
| | 2018 | 2018 | SIVEC BIOTECHNOLOGIES LLC | 1900 E SEADRIFT DR UNIT A | WINDSOR | CO | 80550-3572 | WELD | USA | R43AI140243 | A versatile transkingdom platform for therapeutic nucleic acid delivery to mucosal epithelial tissues | 001 | 1 | NIH | 8/29/2018 | -$293,142 |
|
|
